Anti-THBD Antibody, clone 1I11 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Thrombomodulin (UniProt: P07204; also known as TM, Fetomodulin, CD141) is encoded by the THBD (also known as THRM) gene (Gene ID: 7056) in human. Genetically, the intronless THBD gene (chromosome 20p11.21) encodes this protein and rare coding variants confer susceptibility to venous thromboembolism and, atypical hemolytic‑uremic syndrome (aHUS) by impairing complement and coagulation regulation. THBD serves as a high-affinity receptor for all thrombin forms and acts as a cofactor for the thrombin-dependent activation of protein C. It forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C, which then in combination with its cofactor protein S, acts as an anticoagulant by inactivating factors Va and VIIIa. THBD is also reported to play a role in downregulating fibrinolysis and inflammation through activation of thrombin-activatable fibrinolysis inhibitor (TAFI). Thrombomodulin is a single-pass type I membrane protein that is constitutively expressed on the surface of vascular endothelial cells. THBD is synthesized with a signal peptide (aa 1-18), which is subsequently cleaved off to generate the mature form that contains a long extracellular domain (aa 19-515), a transmembrane domain (aa 516-539), and a cytoplasmic domain (540-575). Its extracellular region contains a C-type lectin domain, multiple EGF like domains and a binding site (aa 481-515) for alpha-L/beta-2 and alpha-M/beta-2 integrin. Clinically, elevated circulating (soluble) THBD levels are observed in disorders of endothelial dysfunction, including sickle cell anemia, where high plasma THBD predicts risk of multiorgan failure and disease severity. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Ruiz, MA., et al. (2021). Am J Hematol. 97(3); E102 E105; Stearns-Kurosawa, DJ et al., (1996). Proc. Natl. Acad. Sci. USA Vol. 93(19); 10212-10216; Woodley-Cook, J et al. (2006). Mol. Cancer Ther. 5(12); 3303-3311).

KLH-conjugated linear peptide corresponding to 23 amino acids from the N-terminal half, extracellular domain of human THBD.

Quality Control Testing

Evaluated by Western Blotting in MDA-MB-231 cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected THBD in MDA-MB-231 cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected THBD in lysates from THP-1 cells and HaCaT cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected THBD in human placenta tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound THBD peptide with at least one thousand-fold (1,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 1I11 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects THBD. It targets an epitope within 23 amino acids from the N-terminal half, extracellular domain.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.